If David MacLennan were CEO of any company but Cargill, he'd be in trouble right now. Since taking over the top job last December, earnings are down 22% to $1.2 billion over his first three quarters. His aggressive plan to build a $370 million new chicken-processing plant in China has been a bust, running directly into an avian flu scare and heightened competition. And the company has become entangled in the global hysteria over the safety of genetically modified foods, losing more than $90 million when Chinese officials started rejecting Cargill's shipments of corn containing a yet-to-be-approved GMO.
展开▼
